Roche

AstraZeneca’s Imfinzi fails first-line bladder cancer test

It also delays further competition to Roche’s rival PD-L1 inhibitor Tecentriq (atezolizumab), which became the first checkpoint inhibitor to be approved for first-line bladder cancer therapy in patients ... Last year, Roche also showed that Tecentriq

China backs use of Roche’s Actemra for coronavirus

Anti-inflammatory drug will be used in patients with lung complications. China has given a green light to use Roche’s anti-inflammatory drug Actemra in coronavirus patients with lung complications ... Roche confirmed in a post that it had donated

Takeda begins development of COVID-19 plasma therapy

China has also approved Roche’s anti-inflammatory drug Actemra (tocilizumab) for the treatment of coronavirus patients with lung complications from the disease, with Roche reportedly donating nearly $2m-worth of

BMS partners with Voluntis to co-develop oncology digital therapeutics

Aside from Sanofi and BMS, Voluntis also has an agreement with Roche for a digital therapeutic for anticoagulation treatments, and a partnership with AstraZeneca for an app designed to aid patients

Celgene’s Revlimid scores NICE approval in follicular lymphoma

Revlimid (lenalidomide) has been recommended for use with Roche’s MabThera (rituximab) – also known as R2 regimen – for the treatment of adult patients with previously-treated grade 1 to 3A follicular

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]